Air Liquide was granted approval to market pharmaceutical product xenon for anesthesia in Germany.
This approval is the key step in the growth strategy of the pharmaceutical activity of Air Liquide.
The approval of the new medical application provides Air Liquide the opportunity to grow in the medical market. Millions of surgical procedures are performed (using general and local anesthetics) every year and therefore the medical market offers great potential for the company.
Xenon for anesthesia is planned to accelerate the further development of xenon applications for patient groups such as pregnant women and small children, for whom there are only a small number of authorised anesthetics available today.
... to continue reading you must be subscribed
